NLS Pharmaceutics AG: NLS Pharmaceutics Successfully Appeals

ZURICH, SWITZERLAND / ACCESSWIRE / November 14, 2022 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and

Related Keywords

Switzerland , Zurich , Züsz , Swiss , Alex Zwyer , Cindy Rizzo , Nasdaq Hearings Panel The , Exchange Commission , Nasdaq Stock Market , European Medicines Agency , Drug Administration , Nasdaq , Pharmaceutics Ltd , Nasdaq Hearings Panel , Listing Rule , Exception Period , Orphan Disease Designation , Mazindol Controlled Release , Orphan Drug Designations , Pharmaceutics , Uccessfully , Appeals , Elisting , Notice ,